#Oncology

Patients with resectable non-small cell lung cancer (NSCLC) remain at high risk of relapse despite perioperative treatment1-3. NeoCOAST-2 (NCT05061550), a phase 2, randomised platform trial, tested novel perioperative treatments in patients with stage…

The tender offer is expected to commence within five business days following the date of the merger agreement. The transaction is expected to close in the financial year 2026-27, subject to satisfaction of all closing conditions.

Health New Zealand Southern has apologised for multiple delays to the treatment of a young man’s eye which led to the growth of a cancerous tumour....

The Japanese drugmaker aims to more than double oncology revenue to above ¥2.3 trillion by 2030 and become one of the world's top five oncology players by 2035.

Hematology Oncology Consultants suffered a ransomware attack by the Rhysida group, resulting in the theft of patient medical records and Social Security numbers.…